Nautilus Biotechnology is trading 12.82% lower at $2.38, with no verified November 2 company-specific catalyst identified. - Its latest reported results were released October 27. - Recent coverage noted a Roth Capital price-target increase, but it does not establish a reason for the decline. - The broader indices provided are rising, so they do not explain the stock’s decline.